MiMedx Group (NASDAQ:MDXG - Get Free Report) is expected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect MiMedx Group to post earnings of $0.07 per share and revenue of $89.42 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
MiMedx Group Trading Up 1.7 %
Shares of MDXG stock traded up $0.13 on Friday, hitting $7.98. The stock had a trading volume of 607,700 shares, compared to its average volume of 566,238. The company's 50 day moving average price is $8.86 and its 200-day moving average price is $7.63. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14. The firm has a market capitalization of $1.17 billion, a P/E ratio of 14.51 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.
Analyst Ratings Changes
Separately, StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $12.00.
View Our Latest Analysis on MiMedx Group
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
See Also
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
